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Oroxylin A promotes PTEN-mediated negative
regulation of MDM2 transcription via SIRT3mediated deacetylation to stabilize p53 and
inhibit glycolysis in wt-p53 cancer cells
Kai Zhao1, Yuxin Zhou1, Chen Qiao1, Ting Ni1, Zhiyu Li2, Xiaotang Wang3, Qinglong Guo1, Na Lu1* and Libin Wei1*

Abstract
Introduction: p53 plays important roles in regulating the metabolic reprogramming of cancer, such as aerobic
glycolysis. Oroxylin A is a natural active flavonoid with strong anticancer effects both in vitro and in vivo.
Methods: wt-p53 (MCF-7 and HCT116 cells) cancer cells and p53-null H1299 cancer cells were used. The glucose
uptake and lactate production were analyzed using Lactic Acid production Detection kit and the Amplex Red Glucose
Assay Kit. Then, the protein levels and RNA levels of p53, mouse double minute 2 (MDM2), and p53-targeted glycolytic
enzymes were quantified using Western blotting and quantitative polymerase chain reaction (PCR), respectively.
Immunoprecipitation were performed to assess the binding between p53, MDM2, and sirtuin-3 (SIRT3), and the
deacetylation of phosphatase and tensin homolog (PTEN). Reporter assays were performed to assess the transcriptional
activity of PTEN. In vivo, effects of oroxylin A was investigated in nude mice xenograft
tumor-inoculated MCF-7 or HCT116 cells.
Results: Here, we analyzed the underlying mechanisms that oroxylin A regulated p53 level and glycolytic metabolism
in wt-p53 cancer cells, and found that oroxylin A inhibited glycolysis through upregulating p53 level. Oroxylin A did
not directly affect the transcription of wt-p53, but suppressed the MDM2-mediated degradation of p53 via
downregulating MDM2 transcription in wt-p53 cancer cells. In further studies, we found that oroxylin A induced
a reduction in MDM2 transcription by promoting the lipid phosphatase activity of phosphatase and tensin homolog,
which was upregulated via sirtuin3-mediated deacetylation. In vivo, oroxylin A inhibited the tumor growth of nude
mice-inoculated MCF-7 or HCT116 cells. The expression of MDM2 protein in tumor tissue was downregulated by
oroxylin A as well.
Conclusions: These results provide a p53-independent mechanism of MDM2 transcription and reveal the potential of
oroxylin A on glycolytic regulation in both wt-p53 and mut-p53 cancer cells. The studies have important implications
for the investigation on anticancer effects of oroxylin A, and provide the academic basis for the clinical trial of oroxylin
A in cancer patients.
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Introduction
p53 gene is one of the most highly studied tumor suppressors, and is often considered as the ‘cellular gatekeeper’ [1]. By responding to the constant bombardment
of various stresses against cell survival, p53 functions
diligently and faithfully, promoting cell cycle arrest,
apoptosis, cellular senescence, or differentiation through
different mechanisms [2]. p53 acts as a critical ‘node’ in
the cellular circuitry, yet it is mutated in over 50% of all
human tumors, which makes the development of novel
anticancer drugs targeting p53 difficult [3]. As the first
tumor suppressor gene is shown to be involved in the
regulation of tumor metabolism, p53 plays important
roles in metabolic regulation, in addition to its established roles in cell survival and apoptosis.
The metabolic changes that occur in cancer cells have
been known for decades; however, the complexity and
importance of those changes have only been understood
in recent years. The metabolic switch from oxidative
phosphorylation to aerobic glycolysis facilitates the
growth of cancer cells. By regulating the levels of a series
of gene products that affect metabolic fates and metabolic products, p53 helps to slow down glycolysis and
promote oxidative phosphorylation [4]. For example,
p53 upregulates the expression of synthesis of cytochrome c oxidase 2 (SCO2) and TP53-induced glycolysis
and apoptosis regulator (TIGAR), whereas it downregulates the expression of phosphoglycerate mutase (PGM)
and glucose transporters 1 and 4 (GLUT1, GLUT4)
[5-8]. Therefore, many drugs targeting energy metabolism are in development.
p53 modulates many key glycolytic enzymes as a specific
transcription factor. The activity of p53 is significant and
highly regulated by post-translational modifications,
protein-protein interactions, and protein stabilization. In
unstressed cells, p53 levels are kept low through its continuous degradation. Mouse double minute 2 (MDM2),
the predominant negative regulator of p53, normally
maintains p53 at low levels. MDM2 (also called HDM2 in
humans), the expression of which is regulated by p53, can
bind to and inactivate p53, transporting it from the nucleus to the cytosol. MDM2 also functions as ubiquitin ligase and covalently attaches ubiquitin to p53, marking the
protein for degradation by the proteasome [9]. Several
mechanisms are activated to promote the rapid accumulation of p53, including the post-translational modification
of p53 and MDM2, subcellular redistribution, inhibition of
MDM2 activity, and direct repression of MDM2 transcription [10].
Sirtuin-3 (SIRT3) is a member of the SIRT family of
proteins, which are class III NAD + -dependent histone
deacetylases that are involved in a variety of functions
including the regulation of metabolism, aging, and carcinogenesis [11]. SIRT3, as a mitochondrial tumor
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suppressor protein, is responsible for several actions that
depend on its mitochondrial milieu, including the considerable deacetylation of mitochondrial proteins, along
with a decrease of glycolysis and ATP levels [12]. In
addition to its reported mitochondrial function, the existence of a small pool of active nuclear SIRT3 has been
proposed. This pool consists of the long form of SIRT3
and has been suggested to have histone deacetylase activity [13].
In the previous studies, we showed that oroxylin A
(OA), a flavonoid isolated from scutellaria root, inhibited
cell growth and induced apoptosis in various cancer
cells, such as human breast cancer MCF-7 and MDAMB-231 cells [14] and human colon cancer HCT116
and HT29 cells [15,16]. Oroxylin A inhibited glycolysis
by promoting the SIRT3-mediated deacetylation of
cyclophilin D in breast carcinoma. Moreover, oroxylin A
stabilized p53 expression at the post-translational level
by downregulating MDM2 expression [17]. It was reported that SIRT3 inhibited cancer cell growth by reducing MDM2-mediated p53 degradation. However, the
underlying mechanism remains unclear. Therefore, in
the present study, we further investigated the mechanism underlying the regulation of oroxylin A on p53 degradation involved in the SIRT3-mediated deacetylation.
We found that oroxylin A remarkably inhibited aerobic
glycolysis in wt-p53 cancer cells and suppressed MDM2mediated degradation of p53 through inhibiting SIRT3modulated transcription of MDM2. Furthermore, SIRT3
played critical roles in the oroxylin A-induced deacetylation of the phosphatase and tensin homolog (PTEN),
resulting in the negative transcription of MDM2. Some
other reports also demonstrate that PTEN blocks
MDM2 nuclear translocation and destabilizes the
MDM2 protein [18]. Taken together, our studies expand
the knowledge of the post-transcriptional regulation of
MDM2 and reveal a novel mechanism to explain the anticancer effect of oroxylin A.

Results
Oroxylin A inhibited p53-regulated glycolysis in wt-p53
cancer cells

In previous studies, we found that oroxylin A inhibited
the cell growth of wt-p53 cancer cell lines MCF-7 and
HCT116 cells. Here, we investigated the influence of
oroxylin A on aerobic glycolysis of these cancer cells.
Oroxylin A (100 and 200 μΜ) inhibited the glucose uptake and lactate production in MCF-7 and HCT116 cells
(Figure 1A, B). Transfection of cells with small interference RNA (siRNA) targeting wt-p53 abolished the inhibitory effects of oroxylin A on glucose uptake and
lactate production in wt-p53 cancer cells (Figure 1C, D).
To determine the importance of p53 in the glycolytic inhibitory effects of oroxylin A, p53-null H1299 cancer
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Figure 1 P53 plays an important role in oroxylin A-induced suppression of glycolysis. (A, B) Wt-p53 cancer cells (MCF-7 and HCT116) were treated
with oroxylin A (100 and 200 μΜ) for 48 h. (A) Glucose uptake was measured using the Amplex Red assay. (B) Production of lactic acid was assayed by
Lactic Acid production Detection kit. (C, D) MCF-7 and HCT116 were transfected with siRNA targeting wt-p53 or with a non-targeting control siRNA,
then incubated with 200 μM oroxylin A for 48 h. Glucose uptake (C) and lactate production (D) were detected. (E, F) Cells were transfected with a
cDNA clone targeting wt-p53, or mut-p53 or with a non-targeting vector. Cells were then incubated with 200 μM oroxylin A for 48 h. Glucose uptake
(E) and lactate production (F) were detected. Bars, SD; *p < 0.05 or **p < 0.01 versus non-treated control.

cells were transfected with wt-p53 cDNA or mut-p53
cDNA (R249S). As a result, only the cells expressing wtp53 cDNA appeared with decreased glycolysis and promoted the inhibitory effects of oroxylin A on glycolysis;
the cells transfected with the mut-p53 cDNA were
against oroxylin A’s effects and could not reverse the

decrease of glucose uptake and lactate generation induced by oroxylin A (Figure 1E, F).
Then, we further investigated the effects of oroxylin A
on the expression of TIGAR, PGM, and GLUT4, which
are target genes of p53 and are responsible for glucose metabolism. As shown in Figure 2A, oroxylin A increased p53
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Figure 2 Oroxylin A downregulates the protein and mRNA expression of p53-related glycolytic pathway components. (A) MCF-7 and HCT116
cells were treated with oroxylin A (100 and 200 μΜ) for 48 h. Western blot assays were performed for the p53-targeted gene products p53, TIGAR,
PGM, and GLUT4. (B) H1299 cells were transfected with a cDNA clone targeting wt-p53 or with a non-targeting vector, then incubated with
200 μM oroxylin A for 48 h. Western blot assays were performed for the p53-targeted gene products TIGAR, PGM, and GLUT4. (C) The gene
expressions of p53, MDM2, and p53-targeted genes were detected by Quantitative RT-PCR. (D) MCF-7 and HCT116 were transfected with siRNA
targeting wt-p53 or with a non-targeting control siRNA, then incubated with 200 μM oroxylin A for 48 h. Western blot assays were performed for
the p53-targeted gene products TIGAR, PGM, and GLUT4. All the Western Blot bands were quantified. Bars, SD; *p < 0.05 or **p < 0.01 versus
non-treated control.

protein level, induced the expression of TIGAR, and inhibited the expressions of PGM and GLUT4 in MCF-7 and
HCT116 cells. Transfection of H1299 cells with wt-p53
cDNA upregulated the protein expression of TIGAR and
downregulated the protein expressions of PGM and
GLUT4 (Figure 2B). Assessment of the mRNA expression
levels of p53 and p53-targeted genes showed that oroxylin A increased the mRNA expression of TIGAR and
decreased that of PGM and GLUT4, but had little influence on p53 mRNA level (Figure 2C). Moreover, the
deletion of p53 in MCF-7 and HCT116 cells reversed
the influence of oroxylin A on p53-targeted protein expressions (Figure 2D).
These results suggested that p53 played important roles
in the oroxylin A-induced suppression of glycolysis.
Oroxylin A inhibited glycolysis in wt-p53 cancer cells
through suppressing MDM2-mediated p53 degradation

Based on the above results, oroxylin A increased the p53
protein level in MCF-7 and HCT116 cells, but had little influence on the transcriptional level of p53. Therefore, we
used cycloheximide (CHX), an inhibitor of protein synthesis, and found that oroxylin A still upregulated the expression of p53 upon the co-treatment of CHX (Figure 3A).

These data further suggested that oroxylin A modulates wtp53 expression at the post-translational level.
Since MDM2 is critical in promoting wt-p53 degradation
via the proteasome pathway, we examined whether MDM2
was involved in the oroxylin A-mediated upregulation of
p53. The results showed that oroxylin A decreased MDM2
mRNA and protein levels (Figures 2C and 3B). In the presence of MG132, an inhibitor of proteasome-mediated proteolysis, oroxylin A-increased wt-p53 protein expression
was changed minimally (Figure 3C), indicating that oroxylin
A increased p53 levels by suppressing MDM2-modulated
proteasomal degradation. Moreover, oroxylin A did not
affect the binding of wt p53 and MDM2 (Figure 3D).
Besides ubiquitination, phosphorylation and acetylation are post-translational modifications to p53 that
have a profound effect on p53 stability and function. In
our previous studies, oroxylin A promoted glycolysis in
human breast cancer cells by upregulating SIRT3, which
is an NAD + -dependent deacetylase. To investigate
whether oroxylin A could influence the stability of p53
via SIRT3-mediated acetylation, the binding of SIRT3
with p53 was assessed by co-immunoprecipitation. As
shown in Figure 3E, p53 could not bind with SIRT3 directly and oroxylin A had no effect on their binding.
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(See figure on previous page.)
Figure 3 Oroxylin A enhances p53 expression through post-transcriptional regulation. (A) Cells were treated with oroxylin A (100 and 200 μΜ)
for 48 h. Western blot assays were performed for MDM2. (B) Effect of oroxylin A on p53 expression after co-treatment with CHX. Cells were
treated with vehicle or oroxylin A for 48 h, and 6 h before harvested, 10 μg/ml CHX was added to the medium. p53 protein expression was
detected by Western blotting. (C) Effect of oroxylin A on p53 expression after co-treatment with MG132. Cells were treated with oroxylin A for
48 h, and 6 h before harvested, 4 μM MG132 was added to the medium. p53 expression was detected by Western blotting. (D) MDM2 was
immunoprecipitated using p53 (Ab6) antibodies. Western blot assays were performed for MDM2, p53. (E) p53 (Ab6) was immunoprecipitated
using anti-SIRT3 antibody. Western blot assays were performed for p53 and SIRT3. All the Western blot bands were quantified.

Taken together, these results indicated that oroxylin A
inhibited p53 degradation by downregulating MDM2
expression.

levels and p53-related pathways by oroxylin A is mediated
by SIRT3.
Oroxylin A downregulates the transcription of MDM2
through PTEN

The regulation of p53 by oroxylin A is mediated by SIRT3

SIRT3 has been shown to inhibit MDM2-mediated p53
degradation [19], and we found that SIRT3 had no direct
effects on p53 stability. Therefore, we investigated
whether the effect of oroxylin A on p53-related pathways was involved with SIRT3. Oroxylin A increased the
protein expression of SIRT3 (Figure 4A). Transfection of
cells with SIRT3 cDNA downregulated the expression of
MDM2 (Figure 4B) Transfection of MCF-7 and HCT116
cells with siRNA targeting SIRT3 reversed the oroxylin
A-induced upregulation of TIGAR and p53 and downregulation of PGM, GLUT4, and MDM2 (Figure 4C). Taken
together, these results suggested that the regulation of p53

Our previous results suggested that oroxylin A could inhibit p53 degradation by downregulating MDM2 expression instead of influencing p53 mRNA level, which was
mediated by SIRT3. The result that oroxylin A increased
p53 levels suggested that oroxylin A must act through
negative feedback on MDM2 transcription through the
P2 promoter in wt-p53 cancer cells. However, the expression of SIRT3 still influenced the level of MDM2 in
p53-null cells (Figure 4B). This inferred the possibility
that oroxylin A may function via a p53-independent
mechanism to regulate MDM2 transcription. For this
purpose, a genomic DNA fragment containing the P1
promoter regions of the MDM2 gene only was ligated to

Figure 4 The oroxylin A regulation of p53, MDM2 and p53-related glycolytic pathway components is SIRT3-dependent. (A) Cells were treated
with oroxylin A (100 and 200 μΜ) for 48 h. Western blot assays were performed for SIRT3. (B) H1299 cells were transfected with a cDNA clone
targeting SIRT3 or with a non-targeting vector, and then incubated with 200 μM oroxylin A for 48 h. Western blot assays were performed for p53,
MDM2, and SIRT3. (C) Cells were transfected with siRNA targeting SIRT3 or with a non-targeting control siRNA and incubated with 200 μM
oroxylin A for 48 h. Western blot assays were performed for p53, MDM2, and the p53-targeted gene products TIGAR, PGM, and GLUT4. All the
Western Blot bands were quantified.
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a luciferase reporter gene. A luciferase assay showed that
oroxylin A inhibited the transcription of MDM2 in wtp53 MCF-7 and HCT116 cells (Figure 5A) as well as in
p53-null H1299 cells (Figure 5B).
PTEN modulates MDM2 transcription by negatively
regulating its P1 promoter [20]. Therefore, we tried to
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verify the direct modulation of PTEN on the MDM2
transcription by co-transfecting wt-PTEN plasmids with
pGL3Basic-Mdm-P1-P2-luc, pGL3Basic-Mdm-P1-luc, or
pGL3 Basic-Mdm-T1-luc (see the plasmid constructs in
Additional file 1: Figure S2) in PTEN-null cell lines
PC3M cells. As a result, wt-PTEN was co-transfected

Figure 5 Oroxylin A inhibits the transcription of MDM2 via PTEN. (A) MCF-7 and HCT116 cells were transfected with an MDM2 promoter luciferase
reporter plasmid (pGL3Basic-Mdm-P1-luc) and then treated with oroxylin A for 48 h. Luciferase activity was normalized to Renilla activity and expressed
as luciferase/Renilla relative units. (B) H1299 cells were transfected with an MDM2 promoter luciferase reporter plasmid (pGL3Basic-Mdm-P1-luc) and
then treated with oroxylin A for 48 h. Luciferase activity was measured. (C) Wt-PTEN plasmids were respectively co-transfected with MDM2 promoter
luciferase reporter plasmids (pGL3Basic-Mdm-P1-luc, pGL3Basic-Mdm-T1-luc, or pGL3Basic-Mdm-P1-P2-luc) into PC3M cells. Luciferase activity was
measured. (D) PTEN siRNA were respectively co-transfected with MDM2 promoter luciferase reporter plasmids (pGL3Basic-Mdm-P1-luc, pGL3BasicMdm-T1-luc, or pGL3Basic-Mdm-P1-P2-luc) into DU145 cells. Luciferase activity was measured. (E) Cells were treated with oroxylin A for 48 h. Western
blot assays were performed for PTEN. (F) Nucleus and cytosolic fractions were isolated after treatment and subjected to Western blot analysis for PTEN.
(G) Immunofluorescence experiment performed in MCF-7 and HCT116 cells upon oroxylin A treatment using antibodies specific to PTEN and DAPI. (H)
PTEN siRNA were respectively co-transfected with MDM2 promoter luciferase reporter plasmids (pGL3Basic-Mdm-P1-luc, pGL3Basic-Mdm-T1-luc, or
pGL3Basic-Mdm-P1-P2-luc) into DU145 cells. Cells were then treated with 200 μΜ oroxylin A for 48 h. Luciferase activity was measured. (I) MCF-7 and
HCT116 cells were transfected with siRNA targeting PTEN or with a non-targeting control siRNA, then incubated with 200 μM oroxylin A for 48 h. The
mRNA expression of MDM2 was detected by Quantitative RT-PCR. (J) Cells were transfected with siRNA targeting PTEN or with a non-targeting control
siRNA and incubated with 200 μM oroxylin A for 48 h. Western blot assays were performed for p53, MDM2, and PTEN. All the Western Blot bands were
quantified. Bars, SD; *p < 0.05 or **p < 0.01 versus non-treated control.
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with the P1 promoter or P1-P2 promoter showed a significant increase in MDM2 transcriptional activity. Instead, wt-PTEN co-transfected with the T1 promoter
had little effect (Figure 5C). Moreover, the deletion of
PTEN decreased in the MDM2 transcriptional activity of
wt-PTEN DU145 cells transfected with P1 promoter
(Figure 5D).
Then, we investigated the effects of oroxylin A on
PTEN. As shown in Figure 5E, oroxylin A had no significant effect on the expression of PTEN. However, we found
that the protein level of PTEN in the cytosol decreased
and instead increased in the nucleus (Figure 5F). And
oroxylin A promoted the translocation of PTEN from the
cytosol to the nucleus (Figure 5G). In further studies, deletion of PTEN reversed the oroxylin A-downregulated
transcriptional activity of MDM2 in DU145 cells transfected with P1 promoter or P1-P2 promoter, instead having no effects in DU145 cells transfected with T1
promoter (Figure 5H). Moreover, siRNA-mediated silencing of PTEN reversed the oroxylin A-induced decrease of
the mRNA and protein levels of MDM2 (Figure 5I, J).
These results suggested that oroxylin A downregulated
the mRNA expression of MDM2 via promoting PTENmediated negative transcription.
SIRT3-mediated deacetylation increased PTEN lipid
phosphatase activity, which was responsible for oroxylin
A-induced negative regulation of MDM2 transcription

Human SIRT3 is expressed as a full-length 44-kDa protein and cleaved via the mitochondrial matrix processing
peptidase (MPP) to a short 28-kDa protein, which is important for SIRT3 enzymatic activity [21]. However, the
existence of a small pool of active nuclear SIRT3 has
been proposed. This pool, consisting of the long form of
SIRT3, has been suggested to have histone deacetylase
activity [13]. Since the regulation of MDM2 levels by
oroxylin A was mediated by SIRT3 and regulated by
PTEN, we examined a potential link between PTEN and
SIRT3. For this purpose, we assessed the binding between SIRT3 and PTEN by immunoprecipitation of nuclear proteins in MCF-7 and HCT116 cells. The results
showed that full-length SIRT3 could bind with PTEN
in the nucleus, and oroxylin A promoted this binding
(Figure 6A). Moreover, oroxylin A decreased the acetylation of PTEN in MCF-7 and HCT116 cells (Figure 6B).
PTEN activity is regulated by acetylation, and the
SIRT1 deacetylase is mainly responsible for PTEN deacetylation [22]. We then examined whether the negative
transcriptional regulation of MDM2 effect via PTEN induced by oroxylin A was involved in the deacetylase activity
of SIRT3. As shown in Figure 6C, siRNA-mediated silencing of SIRT3 promoted the transcription of the MDM2
gene and reversed the oroxylin A-induced suppression of
MDM2 transcription. Moreover, overexpression of SIRT3
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showed the same effects as oroxylin A, decreasing the
acetylation of PTEN and the level of MDM2 as well as inhibiting the transcription of the MDM2 gene, whereas nicotinamide (NAM, SIRT inhibitor) reversed these effects
(Figure 6D, E).
It has been reported that the transcriptional activity of
PTEN is associated with its lipid phosphatase activity
[20]. To investigate whether the transcription of MDM2
was related to PTEN lipid phosphatase activity, the lipid
phosphatase inhibitor, sodium orthovanadate (SO), was
used as a positive control [23]. As shown in Figure 6F,
the gene expression of MDM2 was increased by SO in
MCF-7 and HCT116 cells. As well, MCF-7 and HCT116
cells transfected with P1 promoter had increased transcription of MDM2 by SO (Figure 6G). Acetylation
played a potential role in regulating PTEN function [22],
which was mainly achieved lipid phosphatase activity.
The lipid phosphatase activity of PTEN was increased by
oroxylin A or overexpression of SIRT3, but decreased by
NAM (Figure 6H).
The above results demonstrated that the SIRT3mediated deacetylation of PTEN increased MDM2 transcription and PTEN lipid phosphatase activity. However,
MNAM was the inhibitor of SIRT3 as well as SIRT1.
Therefore, to make sure that the effects of oroxylin A can
really be attributed to SIRT3-mediated, and not SIRT1mediated deacetylation of PTEN, we used tenovin-1 for
further investigation. Tenovin-1 was a small-molecule p53
activator, which inhibited SIRT1 and SIRT2 at low levels,
as well as SIRT3 at higher levels [24]. Therefore, to avoiding the influence of p53, we used p53-null H1299 cells for
investigation. As shown in Figure 6I–K, tenovin-1 inhibited deacetylation of PTEN, decreased the lipid phosphatase activity of PTEN, and suppressed the transcription of
MDM2. When H1299 cells were treated with both
tenovin-1 and oroxylin A, tenovin-1 had little influence on
the effects of oroxylin A. Moreover, the increased lipid
phosphatase activity by oroxylin A was reversed by the deletion of SIRT3 (Figure 6L). These results suggested that
SIRT3, instead of SIRT1, played a critical role in the deacetylation of PTEN induced by oroxylin A, resulting in the
promotion of PTEN lipid phosphatase activity, and the decreased transcription of MDM2.
The deacetylation of PTEN mediated by oroxylin A played
important roles in the regulation of glycolysis in cancer
cells

In our studies, we had found that oroxylin A opposed
glycolysis via p53 and stabilized p53, which was resulted
from the PTEN-regulated negative transcription of
MDM2. Moreover, the deacetylation of PTEN increased
the transcriptional activity of PTEN. Certainly, PTEN affects glycolysis [25], but the role of acetylation is not
well defined. In our further studies, by overexpressing
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(See figure on previous page.)
Figure 6 Oroxylin A inhibited transcription of MDM2 by promoting SIRT3-regulated lipid phosphatase activity of PTEN. (A) Cells were treated with
oroxylin A (OA) for 48 h. Nuclei were isolated and PTEN was immunoprecipitated using anti-FL SIRT3 antibody. Western blot assays were performed for
PTEN and FL SIRT3. (B) Nuclei were isolated and acetylated PTEN was immunoprecipitated using anti-PTEN antibody. Western blot assays were
performed for acetylated-lysine and PTEN. (C) Cells were co-transfected with MDM2 promoter luciferase reporter plasmid (pGL3Basic-Mdm-P1-luc) and
siRNA targeting SIRT3, then incubated with OA for 48 h. Luciferase activity was measured. (D, E) Cells were transfected with SIRT3 cDNA or treated with
OA firstly. Then both were treated with NAM for 48 h. (D) Nuclei were isolated and Western blot assays were performed for MDM2, acetylated PTEN,
and FL SIRT3. (E) Before treatments, MDM2 promoter luciferase reporter plasmid (pGL3Basic-Mdm-P1-luc) was co-transfected into cells. Luciferase
activity was measured. (F) Cells were treated with sodium orthovanadate (SO) for 48 h. The mRNA expression of MDM2 was detected. (G) Cells were
transfected with MDM2 promoter luciferase reporter plasmids (pGL3Basic-Mdm-P1-luc or pGL3Basic-Mdm-T1-luc), and then treated with SO for 48 h.
Luciferase activity was measured. (H) Cells were treated as that in (D). Lipid phosphatase activity of PTEN was assayed. (I, J, K) H1299 cells were treated
with OA in/without the presence of tenovin-1for 48 h. (I) Nuclei were isolated and Western blot assays were performed for MDM2 and acetylated PTEN.
(J) Before treatment, cells were transfected with MDM2 promoter luciferase reporter plasmid (pGL3Basic-Mdm-P1-luc). Luciferase activity was measured.
(K) Lipid phosphatase activity of PTEN was assayed. (L) Cells were transfected with siRNA targeting SIRT3 and incubated with OA for 48 h. Lipid
phosphatase activity of PTEN was assayed. All the Western blot bands were quantified. Bars, SD; *p < 0.05 or **p < 0.01 versus non-treated control.

wt-PTEN in PTEN-null cell lines PC3M cells or knocking out PTEN in wt-PTEN DU145 cells, we found the
expression of PTEN inhibited glycolysis, and the deletion
of deacetylase SIRT3 promoted glycolysis (Figure 7A, B).
Although the deletion of PTEN in MCF-7 and HCT116
cells reversed the inhibition of glycolysis by oroxylin A
(Figure 7C, D), the inhibition of deacetylated PTEN by
siRNA SIRT3 had more strong influence than the suppression of PTEN expression on the oroxylin Aregulated glycolysis (Figure 7E, F). These results showed
that the deacetylation of PTEN mediated by oroxylin A
played important roles in glycolysis.
Oroxylin A inhibited the growth of nude mice xenograft
tumor-inoculated MCF-7 and HCT116 cells in vivo by
downregulating MDM2 level and p53-regulated glycolytic
proteins

We performed xenograft experiment with HCT-116 or
MCF-7 cells. As shown in Figure 8A, the inhibitory effect
of 100 mg/kg oroxylin A on tumor growth of HCT-116 or
MCF-7 cells were 45.65% and 43.95%, respectively. The inhibitory effect of oroxylin A on HCT116 cells was a little
weaker than 5 Fu (20 mg/kg, the inhibitory rate was
64.14%) and was as strong as that of paclitaxel (PTX)
(15 mg/kg, the inhibitory rate was 50.05%) on MCF-7
cells. The tissue extracted from the tumor samples of nude
mice were used for gene and protein expression assay. As
shown in Figure 8B–D, oroxylin A increased p53 protein
expression in MCF-7 and HCT116 cells and had little effects on its gene expression, while both the protein level
and gene level of MDM2 were decreased by oroxylin A.
Moreover, the protein and gene level of p53-targeting
glycolytic enzyme were changed accordingly, PGM and
GLUT4 were decreased, and TIGAR was increased
(Figure 8B, C).
These data suggested that the inhibition of oroxylin A
on xenograft tumors of HCT-116 or MCF-7 cells were
aroused by the suppression of p53-mediated glycolysis in
some degree.

Discussion
As a hallmark of cancer, the Warburg effect, which consists of the activation of aerobic glycolysis, provides pathologists and clinicians clues to diagnose cancer and
helps to explain how cancerous processes prepare substrates to support rapid cell growth. p53, which is considered a critical ‘node’ of the cellular circuitry, plays
important roles in the metabolic shift of cancer cells by
influencing several aspects of metabolism through different mechanisms. In general, p53 suppresses aerobic glycolysis and promotes mitochondrial respiration through
the transcriptional regulation of target genes, providing
a mechanism for blocking tumorigenesis [4,26]. Here,
we investigated the mechanisms underlying the effect of
oroxylin A on the regulation of p53 and p53-related
glycolytic pathways. We found that the oroxylin A inhibited the MDM2-mediated p53 degradation and glycolysis
in wt-p53 cancer cells. And oroxylin A had a stronger
inhibitory effect on glycolysis in wt-p53 cancer cells than
in mut-p53 cancer cells (Additional file 2: Figure S1A to
Additional file 2: Figure S1D). Furthermore, oroxylin A repressed the PTEN-mediated transcription of MDM2 by
promoting its SIRT3-mediated deacetylation (Figure 9).
The p53 pathway is frequently disrupted in tumor
cells. Therefore, recovering the function of wild-type
p53 and its targets in tumor cells is a significant therapeutic objective. A small-molecule compound, RITA
(p53 activator III), was reported to inhibit glycolytic enzymes and induce robust apoptosis in cancer cells [27].
In addition to the pharmacological activation of wildtype p53, such as the effect of RITA, increasing the stability of the p53 protein is another strategy for restoring
wild-type p53 activity in cancer cells. The protein level
of wild-type p53 is regulated by the HDM2 ubiquitin ligase, which targets p53 for degradation by catalyzing its
ubiquitination. HDM2 inhibitors such as Nutlin 3A can
stabilize p53 and rescue its tumor suppressor function in
cancer cells [28]. However, the antitumor efficacy of agents
that promote a functional p53 is often accompanied by
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Figure 7 Oroxylin A-regulated glycolysis involved in the deacetylation of PTEN. (A) PC3M cells were co-transfected with wt-PTEN plasmids and
siRNA SIRT3. Glucose uptake and lactate production were detected. (B) DU145 cells were co-transfected with PTEN siRNA and SIRT3 cDNA.
Glucose uptake and lactate production were detected. (C, D) MCF-7 and HCT116 cells were transfected with siRNA targeting PTEN or with a
non-targeting control siRNA, then incubated with 200 μM oroxylin A for 48 h. Lactate production (E) and glucose uptake (F) were detected. (E, F)
MCF-7 and HCT116 cells were transfected with siRNA SIRT3, and then treated with 200 μM oroxylin A for 48 h, Lactate production (E) and glucose
uptake (F) were detected. Bars, SD; *p < 0.05 or **p < 0.01.

adverse effects [29,30]. Nutlin 3A carries the risk of enhancing the prosurvival adaptation functions of p53 in some
tumors, promoting the p53-dependent upregulation of
Notch1 and triggering a negative feedback anti-apoptotic

mechanism [31]. In the present study, oroxylin A upregulated p53 protein level by inhibiting the MDM2-mediated
degradation (Figure 3). Notably, oroxylin A showed the potential to overcome the drug resistance caused by the p53-
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Figure 8 Oroxylin A inhibited the growth-transplanted human tumor. Nude mice inoculated with MCF-7 cells were treated with saline control,
oroxylin A (100 mg/kg), and PTX (15 mg/kg). Nude mice inoculated with HCT116 cells were treated with saline control, oroxylin A (100 mg/kg),
and 5-FU (20 mg/kg). (A) The tumor inhibitory rates were calculated. (B) Quantitative RT-PCR on RNA isolated from xenograft tumors. (C) The
tumor tissue protein expressions of xenograft tumors were assayed by immunoblotting. (D) Proteins expression in breast tumor tissue were
assessed by immunohistochemistry. All the Western blot bands were quantified. Bars, SD; *p < 0.05 or **p < 0.01 versus non-treated control.

dependent upregulation of factors that promote the growth
of cancer cells. Oroxylin A affects different cellular pathways and functions as an anticancer drug via multiple effects, including the induction of apoptosis and cell cycle
arrest, the inhibition of angiogenesis, the suppression of
invasion and metastasis, and the reversal of multidrugresistance [32-36]. Therefore, despite the activation of p53dependent cancer-promoting factors, oroxylin A acts by
counteracting cancer-promoting effects through the

activation of different pathways and it modulates p53 levels
to promote its anticarcinogenic effects.
Our results showed that oroxylin A inhibited the
MDM2-dependent degradation of wt-p53. The stabilization
and transcriptional activation of wt-p53 in response to various stresses is crucial for cellular homeostasis. Oroxylin A
inhibited glycolysis by regulating the transcription of the
p53 target genes TIGAR, PGM, and GLUT4, but did not
influence the transcriptional level of p53 (Figure 2C). In
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Figure 9 Schematic diagram describing the effect of oroxylin A on the inhibition of p53 degradation through the suppression of PTEN-regulated
MDM2 expression. Oroxylin A enhanced cellular SIRT3 level, causing the deacetylation of PTEN and promoting its lipid phosphatase activity. The
activated PTEN suppressed the transcription of MDM2, which was responsible for the degradation of p53. As a result, oroxylin A inhibited p53
degradation and the p53-related glycolytic pathway.

mut-p53 cells, oroxylin A did not influence mut-p53 level
and showed different effects on the level of TIGAR, PGM,
and GLUT4 with those in wt-p53 cells (Additional file 2:
Figure S1E and Additional file 2: Figure S1F). Our results
indicated that oroxylin A affected the post-transcriptional
regulation of p53. Ubiquitination, phosphorylation, and
acetylation are post-translational modifications that affect
the levels and activity of p53. Recent findings suggested that
these modifications had a profound effect on p53 stability
and function [37]. Our previous studies suggested that
SIRT3-mediated deacetylation played an important role in
oroxylin A-induced suppression of glycolysis. The inhibition of cellular deacetylases leads to a longer half-life for
endogenous p53 [38]. SIRT1 is the homologous protein of
SIRT3 in the SIRT family, and negatively regulates the
tumor suppressor p53 [39]. Therefore, we considered the
possibility that SIRT3 may play a similar role as SIRT1. Our
results showed that wt-p53 as well as mut-p53 could not
bind with SIRT3, and oroxylin A had no effect on their
interaction (Figure 3F and Additional file 2: Figure S1I).
However, oroxylin A increased SIRT3 protein level in both
wt-p53 cancer cells and mut-p53 cancer cells (Figure 4A
and Additional file 2: Figure S1G). We found that oroxylin
A inhibited p53 degradation via a different mechanism related with SIRT3 instead of influencing the direct action between p53 and SIRT3.
In addition to the modification of p53, MDM2 can be
modified post-transcriptionally to disrupt the p53-MDM2
interaction. Similar to p53, the activity of MDM2 can be
regulated by acetylation [40]. Oroxylin A could not inhibit
the binding of p53 with MDM2 (Figure 3D). However, the
transcription of MDM2 was significantly suppressed by
oroxylin A (Figures 2C and 3B). The human MDM2,

HDM2, is controlled by two different promoters [41,42].
Transcription from the first promoter, P1, is independent
of p53, whereas transcription from the second promoter,
P2, is p53-dependent. As shown in Figure 4B, oroxylin A
decreased the level of MDM2 in null-p53 cancer cells,
suggesting that it modulates MDM2 levels in a p53independent manner. Therefore, we constructed a luciferase reporter gene consisting of the P1 promoter DNA
fragment of the MDM2 gene only and showed that oroxylin A could inhibit the transcriptional activity of MDM2
through a p53-independent mechanism (Figure 5A, B). In
vivo, we showed that oroxylin A inhibited the tumor
growth of wt-p53 MCF-7 and HCT116 cells (Figure 8).
And the inhibitory rate of 100 mg/kg oroxylin A for mutp53 MDA-MB-231 cells was 56.78% (data not shown) and
36.16% for HT29 cells [16]. These results suggested that
oroxylin A had the presence of a p53-independent mechanism as well.
The PTEN tumor suppressor gene is a major tumor
suppressor that physically interacts with p53 and prevents
its degradation by dissociating p53 from the p53-MDM2
complex [43,44]. The overexpression of wt-PTEN in the
PTEN-null cell lines PC3M cells, which were cotransfected with pGL3Basic-Mdm-P1-luc, promoted the
transfection of MDM2, instead in the PTEN-null cell lines
PC3M cells pGL3 Basic-Mdm-T1-luc not (Figure 5C).
Oroxylin A could promote the translocation of PTEN
from the cytosol to the nucleus (Figure 5G). Professor Wu
and his group reported a novel mechanism by which
PTEN modulates MDM2 expression independent of p53
[20]. Our results showed that the deletion of PTEN reversed the oroxylin A-induced suppression of MDM2
transcription (Figure 5H, I). PTEN was shown to control
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MDM2 P1 promoter activity through its lipid phosphatase
activity.
The lipid phosphatase activity of PTEN is critical for
its tumor suppressor function [45]. In addition to phosphorylation and membrane association, which regulate
PTEN activity, acetylation is an important mechanism of
regulation of PTEN function and it involves the activity
of SIRT1 [22]. The deacetylation of the PTEN, as well as
its expression, both influenced glycolysis in cancer cells
(Figure 7). Moreover, we found that SIRT3 induced the
deacetylation of PTEN similar to SIRT1 (Figure 6A, B).
The dependence of p53 level and MDM2 transcription
on SIRT3 highlights the significance of SIRT3 in the anticancer effects of oroxylin A (Figures 4C and 6C). To
make sure whether the effects of oroxylin A were attributed to SIRT3-mediated, and not SIRT1-mediated deacetylation of PTEN, p53-null H1299 cells were treated
with both tenovin-1 and oroxylin A, and found that
tenovin-1 had little influence on the effects of oroxylin
A (Figure 6I–K). Therefore, SIRT3 played a critical role
in the deacetylation of PTEN induced by oroxylin A, but
not SIRT1. Oroxylin A upregulated the lipid phosphatase activity of PTEN via SIRT3-mediated deacetylation.
Interestingly, our results show that the SIRT3-mediated
deacetylation of PTEN occurs in the nucleus rather
than in the mitochondria. Determining the subcellular
localization of SIRT3 is crucial for identifying its targets
and substrates, and elucidating its cellular functions is
crucial as well for the identification of its associated signaling pathways [21]. Although most studies support a
mitochondrial localization and deacetylase activity for
SIRT3 [46,47], others report that both forms of SIRT3
are enzymatically active [13]. Prof. Reinberg Iwahara
et al. report that SIRT3 is capable of histone deacetylase
(HDAC) activity and that the full-length (FL) SIRT3 is
associated with transcriptional repression dependent on
its HDAC activity [48]. Our findings that FL SIRT3 in
the nucleus induced the deacetylation of PTEN suggest
that oroxylin A regulates MDM2 transcription by promoting the deacetylation of PTEN.

Conclusions
Previous studies have shown that the flavonoid oroxylin A
increases p53 levels and inhibits p53-mediated glycolysis
[17,49]. In the present study, we showed that oroxylin A
inhibited glycolysis in wt-p53 cancer cells through the
suppression of p53 degradation. PTEN-mediated suppression of MDM2 transcription is responsible for the increased p53 level. And the lipid phosphatase activity of
PTEN was regulated by the FL SIRT3-mediated deacetylation, playing the key roles in the effects of oroxylin A on
p53. Further understanding of the effects of oroxylin A on
key glycolytic regulatory factors may help reveal critical
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mechanisms for the design of treatments targeting cancer
metabolism.

Materials and methods
Reagents

Oroxylin A (C16H12O5, purity 99.76%, the synthetic
route, structure assay and purity assay; see Additional
file 3: Figure S3 and Additional file 4: Table S1) was isolated from the root of Scutellaria baicalensis Georgi, according to previously reported protocols [50], dissolved
in DMSO as a stock solution at −20°C, and diluted with
a medium before each experiment. The final DMSO
concentration did not exceed 0.1% throughout the study.
SRT 1720 hydrochloride (SRT1720) was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA), dissolved in
DMSO, and prepared to 10−1 M stock solutions. CHX,
MG132 (proteasome inhibitor), and NAM were purchased from Beyotime (Beyotime Institute of BioTechnology, Haimen, China). Tenovin-1 was obtained from
Cayman Chemical Co. (Ann Arbor, MI) and diluted to a
10−1 M concentration in DMSO.
Cell Culture

The human breast cancer cell lines MDA-MB-231 and
MCF-7 and the human colon cancer cell lines HCT-116
and HT-29 were purchased from Cell Bank of Shanghai
Institute of Biochemistry and Cell Biology, Chinese
Academy of Sciences (Shanghai, China). MCF-7 cells
were cultured in and Dulbecco’s MEM (DMEM, Invitrogen Corporation, Carlsbad, CA); HCT-116 was cultured
in McCoy’s 5A Medium (GIBCO, Invitrogen Corporation, Carlsbad, CA), both supplemented with 10% heatinactivated fetal bovine serum (Sijiqing, Hangzhou,
China), 100 U/ml penicillin G, and 100 μg/ml streptomycin at 37°C, 95% relative humidity, and 5% CO2 with
21% oxygen conditions.
Lactic acid production

To measure lactic acid production, cells were treated
with oroxylin A for 48 h, and media were collected and
assayed following the manufacturer’s instructions of the
Lactic Acid production Detection kit (KeyGen, Nanjing,
China). The assay results were detected with a spectrophotometer (Thermo, Waltham, MA) at 570 nm.
Glucose uptake assay

After treatment, media were collected and diluted
1:4000 in water. The amount of glucose in the media
was then detected using the Amplex Red Glucose Assay
Kit (Invitrogen, Eugene, OR) according to the manufacturer’s instructions. Glucose uptake was determined by
subtracting the amount of glucose in each sample from
the total amount of glucose in the media (without cells).
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The detection was performed by spectrophotometer
(Thermo, Waltham, MA) at Ex/Em = 530/590 nm.
Western blot analysis

Protein samples were isolated with lysis buffer, eluted
with SDS buffer, separated on SDS-polyacrylamide gels,
and electroblotted onto PVDF membranes [51]. Immunoreactive protein bands were detected using an Odyssey
Scanning System (LI-COR Inc., Superior St., Lincoln, NE).
The following antibodies were used for Western blotting:
PGM, MDM2, β-actin (Santa Cruz Biotechnology, CA) at
1:400 dilution; SIRT3, hexokinase II, hydroxy-HIF-1α,
PTEN, GLUT4 (Cell signaling Technology, Inc., MA) at
1:800 dilution; SIRT3 of nuclear protein (Abcam Ltd, HK,
China) at 1:1000 dilution; TIGAR (Anspec, Inc., San Jose,
CA); p53 (Ab-6) (EMD Chemicals, Gibbstown, NJ).
Real-time PCR analysis

Total RNA was extracted using the TriPure Isolation Reagent (Roche Diagnostics, Mannheim, Germany) and
then amplified by polymerase chain reaction (PCR). An
aliquot of 1 μg of total RNA was used to transcribe the
first-strand cDNA with SuperScript II reverse transcriptase (Invitrogen, Eugene, OR). Real-time PCR was completed on an ABI PRISM Sequence Detector 7500
(PerkinElmer, Branchburg, NJ) using Sequence Detector
version 1.7 software (Applied Biosystems, Foster City,
CA). SYBR Green PCR Master Mix was purchased from
Applied Biosystems. The primer sets used in the PCR
amplification were listed in Table 1. The relative gene
expressions were analyzed using quantitative RT-PCR
with β-actin as an internal control.
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Full-length SIRT3 was immunocaptured from nuclear extracts using antibodies against full-length SIRT3 (Abcam
Ltd., HK, China) cross-linked to protein G-agarose beads.
The PTEN protein was analyzed by Western blotting and
probed with anti-PTEN antibody.
PTEN was immunocaptured from nuclear extracts
using antibodies against PTEN cross-linked to protein
G-agarose beads. The acetylated PTEN was analyzed by
Western blotting and probed with acetylated-lysine
antibody.
Cell transfection and luciferase reporter assay

The MDM2 luciferase reporter gene plasmid pGL3BasicMdm-P1-P2-luc, pGL3Basic-Mdm-P1-luc, and pGL3BasicMdm-T1-luc were designed according to the studies of
Prof. Hong Wu (Dept. of Molecular and Medical Pharmacology, Howard Hughes Medical Institute, Los Angeles,
CA) [20] and synthesized by Beyotime Institute of BioTechnology (Hangzhou, China) (Additional file 1: Figure S2).
Cells (5 × 105 cells/well) were plated in 6-well plates and
transfected transiently with the pGL3Basic-Mdm-P1-luc
containing the P1 promoter of MDM2 only using Lipofectamine 2000TM reagent (Invitrogen, CA). The plasmid
GL3Basic-Mdm-P1-luc was added to adjust the total
amount of DNA (4 μg/well in a 6-well plate) and the
Renilla luciferase reporter at 0.4 μg/well in a 6-well plate
served as normalization control. Cells were treated with
oroxylin A for 48 h and luciferase assays were performed
with the Luciferase Reporter Gene Assay kit (Promega,
Madison, WI) and detected using Luminoskan ascent
(Thermo, Waltham, MA).

Immunoprecipitation

Plasmid and siRNA transient transfection

SIRT3 was immunocaptured using antibodies against
SIRT3 cross-linked to protein G-agarose beads (Santa
Cruz Biotechnology, CA). The immunocomplexes were
analyzed by Western blotting and probed with antibodies against p53 (Ab-6) and MDM2.
Wt-p53 was immunocaptured using p53 (Ab-6) crosslinked to protein G-agarose beads (Santa Cruz Biotechnology, CA). The immunocomplexes were analyzed by
Western blotting and probed with antibody against
MDM2.

The pCMV-Neo-Bam p53 plasmid containing the
complete sequence of human wt-p53 and the pCMVNeo-Bam p53 R249S plasmid containing the sequence of
human mut-p53 were a gift from Prof. Moshe Oren
(The Weizmann Institute of Science, Rehovot, Israel)
and obtained from Addgene. The siRNAs targeting
sirtuin-3 or sirtuin-3 cDNA were purchased from OriGene (OriGene Technologies, Inc., MD, USA). The siRNAs targeting PTEN were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA).

Table 1 The primer sequence used in the PCR amplification
Gene

Sense

β-actin

5′-CTGTCCCTGTATGCCTCTG-3′

Antisense
5′-ATGTCACGCACGAT-TTCC-3′

p53

5′-CTCCTCAGCATCTTATCCG-3′

5′-AGCCTGGGCATCCTTG-3′

MDM2

5′-CTTGATGCTGGTGTAAGT-3′

5′-GTTGATGGCTGAGAATAG-3′

TIGAR

5′-CAGTGATCTCATGAGGACAAAGCA-3′

5′-CCATGGCCCTCAGCTCACTTA-3′

PGM

5′-TTGAATACA GCGACCCAGTGGA-3′

5′-CTATCGATGTACAGCCGAATGGTG-3′

GLUT4

5′-CTTCATCATTGGCATGGGTTT-3′

5′-AGGACCGCAAATAGAAGGAAGA-3′
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For siRNA transfection, cells were seeded in 6-well
plates. Either p53 siRNA duplexes (30 pmol/l) or PTEN
siRNA was introduced into the cells using siPORT
NeoFX Transfection Agent (Ambion Inc., Austin, TX)
according to the manufacturer’s recommendations.
Then, the cells were exposed to RPMI 1640 medium
with or without oroxylin A and harvested for further
experiments.
For plasmid transfection, plasmid DNA (1 μg) was introduced using PolyJet In Vitro DNA Transfection Reagent (SignaGen Laboratories, Rockville, MD) according
to the manufacturer’s recommendations. Cells were then
exposed to oroxylin A or the vehicle and harvested for
further experiments.
Preparation of nuclear- and cytosol-enriched extracts

After cells were incubated with oroxylin A for 48 h, cell
nuclear and cytoplasmic fractions were prepared using a
nuclear/cytosol fractionation kit of Biovision Inc.
(Mountain View, CA, USA) according to the manufacture’s direction.
Immunofluorescence and confocal fluorescence
microscopy

Cells were fixed with 4% paraformaldehyde in PBS at
1-h intervals, permeabilized with 0.5% Triton X-100, and
blocked with 3% BSA for 30 min. Incubation with primary antibodies against PTEN (Bioworld Technology,
Inc, MN, USA) was done overnight at 4°C. Then, the
nuclei were stained with 4′,6-diamidino-2-phenylindole
(DAPI, Sigma-Aldrich) 20 min before imaging. A laser
scanning confocal microscope FV10-ASW (Ver 2.1)
(Olympus Corp, MPE FV1000, Tokyo, Japan) was used
for colocalization analysis.
PTEN lipid phosphatase activity

For the measurement of in vitro PTEN lipid phosphatase
activity, the malachite green phosphatase assay kit (Echelon
Biosciences, Inc., Salt Lake City, UT) was used according to
the manufacturer’s instructions (see the detailed process in
Additional file 5).
In vivo tumor growth assay

This experiment was conducted in accordance with the
guidelines issued by the State Food and Drug Administration (SFDA of China).
Twenty nude mice were inoculated subcutaneously
with 1 × 107 HCT-116 into the right axilla. After 12 days
of growth, tumor sizes were determined using micrometer calipers. Mice-inoculated HCT-116 cells with similar tumor volumes were randomly divided into the
following three groups (six mice/group): saline control,
oroxylin A (100 mg/kg, i.v., every 2 days), and 5Fluorouracil (5-Fu, 20 mg/kg, i.v., every 2 days).

Page 16 of 18

To facilitate estrogen-dependent xenograft establishment, each mouse received 17-estradiol (20 mg/kg; Sigma)
intraperitoneally once a week. One week after treatment,
equivalent amounts of MCF-7 cells were injected subcutaneously (107 cells/tumor) into the left axilla of nude mice.
After 12 days of growth, tumor sizes were determined
using micrometer calipers. Mice-inoculated MCF-7 cells
with similar tumor volumes were randomly divided into
the following three groups (six mice/group): saline control,
oroxylin A (100 mg/kg, i.v., every 2 days), and PTX
(15 mg/kg, i.v., twice a week).
Tumor sizes were measured every 3 days using micrometer calipers, and tumor volume was calculated
using the following formula: TV (mm3) = d2 × D/2,
where d and D were the shortest and the longest diameters, respectively. Mice were sacrificed on day 21, and
tumor tissues were used for Western blotting, real-time
PCR, and Immunohistochemistry Assay (see the detailed
process in Additional file 5).
Statistical evaluation

Data are presented as mean ± SD from triplicate parallel
experiments unless otherwise indicated. Statistical analyses were performed using one-way ANOVA.

Additional files
Additional file 1: Figure S2. Schematic illustration of MDM2 promoter
and reporter constructs. P1, promoter 1, P2, promoter 2; P1-P2, MDM2
full-length promoter region including both promoters; T1, a serial 5′
truncated Mdm2 promoter construct.
Additional file 2: Figure S1. The effect of oroxylin A on SIRT3, MDM2,
mut-p53, and p53-related glycolytic pathway in mut-p53 cancer cells. (A,
B) wt-p53 cancer cells (MCF-7 and HCT116) and mut-p53 (MDA-MB-231
and HT-29 cells) were treated with oroxylin A (100 and 200 μΜ) for 48 h.
(A) Glucose uptake was measured using the Amplex Red assay. (B)
Production of lactic acid was assayed by Lactic Acid production
Detection kit. (C, D) MDA-MB-231 and HT-29 were transfected with siRNA
targeting wt-p53 or with a non-targeting control siRNA, then incubated
with 200 μM oroxylin A for 48 h. Glucose uptake (C) and lactate
production (D) were detected. (E) MDA-MB-231 and HT-29 cells were
treated with oroxylin A (100 and 200 μΜ) for 48 h. Western blot assays
were performed for the p53-targeted gene products p53, TIGAR, PGM,
and GLUT4. (F) H1299 cells were transfected with a cDNA clone targeting
mut-p53 (R248W) or with a non-targeting vector, and then incubated
with 200 μM oroxylin A for 48 h. Western blot assays were performed for
the p53-targeted gene products TIGAR, PGM, and GLUT4. (G) Western
blot assays were performed for the MDM2 and SIRT3. (H) MDM2 was
immunoprecipitated using p53 (Ab3) antibodies. Western blot assays were
performed for MDM2, mut-p53. (I) p53 (Ab3) was immunoprecipitated using
anti-SIRT3 antibody. Western blot assays were performed for mut-p53 and
SIRT3. All the Western Blot bands were quantified.
Additional file 3: Figure S3. The detailed information of oroxylin A.
(A) The structure and molecular weight of oroxylin A. (B) The synthetic
route of oroxylin A. In the synthesis, baicalein is used as the starting
material, and participated in benzyl reaction to compound (2), which
is methylated to produce compounds (3). Then compound (3) was
participated in palladium hydrogen/carbon reduction reaction to get the
target product oroxylin A. (C) NMR assay for the structure of isolated
sample. 1H-NMR spectra were determined on a Varian Gemini-300 NMR
instrument. (D) MS assay for the structure of isolated sample. Mass spectra
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were recorded on a Finnigan MAT TSQ-46 or Finnigan MAT TSQ-700 mass
spectrometer. The data was listed as below: 1H-NMR (DMSO-d6, 300Hz):
δ3.85 (3H, s, OMe), 6.63 (1H, s, 3H), 6.95 (1H, S, 8H), 7.56-7.59 (3H, m, ArH),
8.05-8.07 (2H, d, ArH), 10.78 (1H, s, 7-OH), 12.92 (1H, s, 5-OH). MS (EI, m/z):
284 (MH1). IR (KBr,υ) cm-1:1653, 3455. (E) IR assay for the structure of isolated
sample. IR spectra were recorded on a Perkin-Elmer FT-IR 1600 series FT-IR
spectrophotometer. (F) The sample was analyzed by HPLC.
Additional file 4: Table S1. The HPLC analysis for purity of oroxylin A.
Additional file 5: Supplementary materials and methods. The
methods for animal model, PTEN lipid phosphatase activity, and
immunohistochemistry were listed.
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